

TERN PLC

SOFTWARE AND COMPUTER SERVICES


4 May 2021

TERN.L

12p

Market Cap: £39.6m

SHARE PRICE (p)



12m high/low 14.3p/5.8p

Source: LSE Data

KEY DATA

Net (Debt)/Cash	£2.1m (at 31/12/20)
Enterprise value	£37.5m
Index/market	AIM
Next news	Interims, Sept 2021
Shares in Issue (m)	330.3
Chairman	Ian Ritchie
Chief Executive	Albert E Sisto
Finance Director	Sarah Payne

COMPANY DESCRIPTION

Tern predominantly invests in software companies, with proven technology, based in the UK but with global ambition.

www.ternplc.com

TERN PLC IS A RESEARCH CLIENT OF PROGRESSIVE

ANALYSTS

Gareth Evans

+44 (0) 20 7781 5301

gevans@progressive-research.com



Gavin Wood

+44 (0) 20 7781 5300

gwood@progressive-research.com



www.progressive-research.com

Exciting times for Tern's portfolio companies

Tern has provided a summary of the progress made by its principal portfolio companies in recent months that will be included in the Chairman's statement at its AGM later today, which will be followed by an online presentation and Q&A session for shareholders. Recent highlights at each of Tern's principal portfolio companies are summarised below. The AGM statement also emphasises Tern's strong focus on generating value for its own shareholders from the investments it has made in this broad portfolio of companies at the forefront of IoT technology, and that the market backdrop appears very favourable, with IDC forecasting the IoT market will maintain double-digit annual growth rates and surpass US\$1tn in 2022.

- Device Authority** – Since launching KeyScaler for Azure Sphere in March 2021, Device Authority has continued to see increased demand for security and management integrations with Microsoft Azure. KeyScaler will support the new FIDO Device Onboard (FDO) protocol platform, enabling all customers to leverage FDO in their IoT projects, believed to be key for realising the wider IoT opportunity. Device Authority has also recently added two experienced hires to its business development team.
- Talking Medicines** – PatientMetRx platform released in February 2021. PatientMetRx provides a systematic measure of the patient experience of medicines for the pharmaceutical industry. The first customer for the platform has been secured and there is significant further interest.
- Wyld Networks** – Significant developments anticipated for Wyld Connect Satellite in 2021 in delivering communications technology via emerging constellations of low earth orbit satellites. Further routes to market secured, including Fujitsu globally and Wezen Group in Latin America. The Wyld Proximity and Safe Access Management care homes solution has seen further interest since its recent BBC TV coverage.
- InVMA** – Recently expanded international relationship with a major industrial and construction sector supplier. InVMA's SaaS asset monitoring platform, AssetMinder, will now be supplied through this partner in France and Belgium in addition to the existing UK deal, with further European expansion anticipated later in 2021.
- FundamentalVR** – Continuing to build on recent contract wins. A further rollout with a key pharmaceutical client demonstrates the focus on securing customers, then expanding the relationship over time.

INVESTEE COMPANIES



FUNDAMENTALVR



This publication should not be seen as an inducement under MiFID II regulations.
Please refer to important disclosures at the end of the document.

Disclaimers and Disclosures


Copyright 2021 Progressive Equity Research Limited (“PERL”). All rights reserved. Progressive’s research is commissioned by the subject company under contract and is freely available to the public and all institutional investors. Progressive does not offer investors the ability to trade securities. Our publications should not, therefore, be considered an inducement under MiFID II regulations. PERL provides professional equity research services, and the companies researched pay a fee in order for this research to be made available. This report has been commissioned by the subject company and prepared and issued by PERL for publication in the United Kingdom only. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable; however, PERL does not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of PERL at the time of publication, and any estimates are those of PERL and not of the companies concerned unless specifically sourced otherwise. PERL is authorised and regulated by the Financial Conduct Authority (FCA) of the United Kingdom (registration number 697355).

This document is provided for information purposes only, and is not a solicitation or inducement to buy, sell, subscribe, or underwrite securities or units. Investors should seek advice from an Independent Financial Adviser or regulated stockbroker before making any investment decisions. PERL does not make investment recommendations. Any valuation given in a research note is the theoretical result of a study of a range of possible outcomes, and not a forecast of a likely share price. PERL does not undertake to provide updates to any opinions or views expressed in this document.

This document has not been approved for the purposes of Section 21(2) of the Financial Services & Markets Act 2000 of the United Kingdom. It has not been prepared in accordance with the legal requirements designed to promote the independence of investment research. It is not subject to any prohibition on dealing ahead of the dissemination of investment research.

PERL does not hold any positions in the securities mentioned in this report. However, PERL’s directors, officers, employees and contractors may have a position in any or related securities mentioned in this report. PERL or its affiliates may perform services or solicit business from any of the companies mentioned in this report.

The value of securities mentioned in this report can fall as well as rise and may be subject to large and sudden swings. In addition, the level of marketability of the shares mentioned in this report may result in significant trading spreads and sometimes may lead to difficulties in opening and/or closing positions. It may be difficult to obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance.



To arrange a meeting with the management team, or for further information about Progressive, please contact:

Emily Ritchie

+44 (0) 20 7781 5311

eritchie@progressive-research.com